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NEJMoa1210093
Relief of profound feedback inhibition
of mitogenic signaling by RAF inhibitors
attenuates their activity in BRAFV600E
melanomas
by Lito P, Pratilas CA, Joseph EW, Tadi M,
Halilovic E,ZubrowskiM, et al. (2012).Can-
cer Cell 22:668–82. doi:10.1016/ j.ccr.2012.
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In drug development, specificity and the
avoidance of off-target effects are the ini-
tial holy grails, with the ultimate goal of
obtaining maximal in vivo efficacy coupled
with minimal toxicity. Tumors, however,
can be very efficient at nullifying the bene-
fits of what could otherwise be good drugs.
Tumors achieve these effects through a
variety of mechanisms, one of which is
drug resistance.
Acquired resistance to cancer therapies
remains a major health problem in oncol-
ogy (1). Targeted therapies inhibit tumor
growth but success is often short-lived as
tumors rapidly evolve a way to bypass the
pharmacologic block via re-activation of
the targeted or parallel pathways. So, what
can be done to overcome acquired resis-
tance and achieve desired outcomes in the
clinic? Perhaps the best defense against
acquired resistance is to come out swing-
ing and deal with it up front, rather than
waiting for the inevitable to occur and sub-
sequently modifying treatment regimens
on the fly.
Two recent papers (2, 3) shed light on a
novel combination therapy strategy to cir-
cumvent acquired resistance in BRAFV600E-
positive melanomas. One is a mechanis-
tic study (3) that shows why combination
therapy may be promising for BRAFV600E-
positive melanomas and that it can work in
xenograft mouse models, while the other,
a clinical study (2), indicates improved
outcome when patients are treated with a
combination of both a BRAFV600E-specific
inhibitor and a MEK inhibitor.
The BRAFV600E mutation is present
in ∼50% of human melanomas (4, 5).
Prior to its discovery as a causal muta-
tion in melanoma,prognosis for melanoma
patients was grim as melanoma is notori-
ously unresponsive to chemo- and radio-
therapies. Following BRAFV600E identifi-
cation, there was a flurry of activity that
culminated in Plexxikon’s development of
vemurafenib (Zelboraf) (6), which was
approved by the FDA in 2011 and the fol-
lowing year saw approval in Canada and
Europe. Moreover, while vemurafenib has
been a boon, promoting tumor regres-
sion and improved survival, acquired
resistance frequently occurs after several
months of vemurafenib treatment lead-
ing to MAP kinase pathway re-activation
(6) that is not blocked by vemurafenib.
How was the resistance happening and
what can be done to minimize resistance
up front?
Now, recent work from the Rosen
lab at Memorial Sloan-Kettering Cancer
Center has uncovered data that vemu-
rafenib reduces feedback inhibition in
BRAFV600E-expressing cells such that these
cells become sensitized to extracellular
growth factors like hepatocyte and epi-
dermal growth factors. Unlike canonical
receptor-mediated RAF signaling, which
utilizes RAF-RAF dimers, BRAFV600E func-
tions as a monomer that is sensi-
tive to RAF inhibition. Vemurafenib and
other BRAFV600E inhibitors like dabrafenib
(GlaxoSmithKline, currently in Phase III
trials) inhibit the BRAFV600E monomer but
are unable to block ligand-mediated RAF-
RAF dimers. Thus, in the context of per-
sistent vemurafenib, feedback inhibition
wanes permitting extracellular mitogens
to bypass vemurafenib-mediated inhibi-
tion since they promote RAF-RAF dimers.
Importantly, the authors go on to show
using four different BRAFV600E melanoma
xenograft mouse models that an effective
dose of Plexxikon’s vemurafenib analog
PLX4720, when combined with a low dose
of the MEK inhibitor PD0325901 promotes
tumor regression in 25/26 tumors. Either
PLX4720 or PD0325901 alone also inhib-
ited tumor growth but less potently that
when combined.
Concurrently, in a recent study pub-
lished in the New England Journal of
Medicine, Flaherty and colleagues pro-
vide promising data from an open-label
trial (2) involving over 400 patients
that a combination of the BRAFV600E
inhibitor, dabrafenib, and a MEK inhibitor
trametinib (GlaxoSmithKline), which is
near approval (7), significantly increased
progression-free survival when compared
to monotherapy. These studies validate
the rationale to try to anticipate acquired
resistance at the onset of therapy, rather
than dealing with it once it has already
occurred.
Going forward, how might targeted
therapies be best designed to overcome
acquired resistance, especially when par-
allel pathways become activated? Recent
work (8) published in Nature from the
Cagan and Shokat labs at Mt. Sinai School
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of Medicine and University of Califor-
nia, San Francisco, CA, USA respectively,
suggests a systems-based strategy to do
just that. In a Drosophila model of Ret-
induced multiple endocrine neoplasia, the
authors show using a rationally designed
single small molecule that balanced inhi-
bition of multiple targets (Raf, Src, and
S6K) was the most efficacious especially
when the molecule was designed to avoid
a so-called “anti-target,” Tor in this case,
to minimize toxicity and relief from feed-
back inhibition. There is cautious opti-
mism that such strategies will have success
in the clinic (1).
Finally, these data raise questions for the
possible future therapies (9) for the devel-
opmental disorders caused by MAP kinase
pathway mutations, collectively referred
to as the RASopathies, and in particular
cardio-facio-cutaneous (CFC) syndrome
in which the majority of cases are caused
by gain-of-function BRAF mutations.
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